Wall Street brokerages expect Bruker Co. (NASDAQ:BRKR) to announce earnings of $0.31 per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Bruker’s earnings, with estimates ranging from $0.28 to $0.36. Bruker reported earnings per share of $0.25 during the same quarter last year, which would suggest a positive year-over-year growth rate of 24%. The business is scheduled to issue its next earnings report on Thursday, August 1st.
On average, analysts expect that Bruker will report full year earnings of $1.62 per share for the current year, with EPS estimates ranging from $1.60 to $1.63. For the next year, analysts anticipate that the company will report earnings of $1.82 per share, with EPS estimates ranging from $1.78 to $1.88. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Bruker.
Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, May 2nd. The medical research company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The business had revenue of $461.40 million for the quarter, compared to analysts’ expectations of $450.46 million. Bruker had a net margin of 9.53% and a return on equity of 26.28%. The company’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.24 EPS.
BRKR has been the topic of several recent research reports. BidaskClub raised shares of Bruker from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 22nd. Deutsche Bank raised shares of Bruker from a “hold” rating to a “buy” rating and boosted their price objective for the company from $40.00 to $50.00 in a research note on Friday, April 12th. Zacks Investment Research cut shares of Bruker from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Leerink Swann raised shares of Bruker from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. Finally, Svb Leerink raised shares of Bruker from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $40.00 to $53.00 in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $48.20.
In other Bruker news, Director Marc A. Kastner sold 1,374 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $41.79, for a total transaction of $57,419.46. Following the sale, the director now directly owns 10,811 shares in the company, valued at approximately $451,791.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Frank H. Laukien sold 400,000 shares of the business’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $41.48, for a total transaction of $16,592,000.00. Following the sale, the chief executive officer now owns 37,991,030 shares in the company, valued at $1,575,867,924.40. The disclosure for this sale can be found here. Insiders have sold a total of 801,374 shares of company stock worth $33,241,419 over the last 90 days. Insiders own 26.50% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace North America L.P. increased its stake in shares of Bruker by 32.8% during the 1st quarter. Marshall Wace North America L.P. now owns 821,680 shares of the medical research company’s stock valued at $31,584,000 after acquiring an additional 203,091 shares during the last quarter. GWM Advisors LLC increased its stake in shares of Bruker by 14.4% during the 1st quarter. GWM Advisors LLC now owns 44,716 shares of the medical research company’s stock valued at $1,719,000 after acquiring an additional 5,620 shares during the last quarter. Qtron Investments LLC acquired a new position in shares of Bruker during the 1st quarter valued at about $251,000. Citigroup Inc. increased its stake in shares of Bruker by 32.3% during the 1st quarter. Citigroup Inc. now owns 44,764 shares of the medical research company’s stock valued at $1,720,000 after acquiring an additional 10,935 shares during the last quarter. Finally, WCM Investment Management LLC acquired a new position in shares of Bruker during the 1st quarter valued at about $1,624,000. Institutional investors and hedge funds own 66.73% of the company’s stock.
Shares of Bruker stock traded up $0.68 during trading on Thursday, reaching $48.95. The company’s stock had a trading volume of 461,200 shares, compared to its average volume of 745,916. The stock has a 50-day moving average price of $43.91. The company has a market capitalization of $7.58 billion, a price-to-earnings ratio of 35.03, a PEG ratio of 2.37 and a beta of 1.26. Bruker has a fifty-two week low of $26.10 and a fifty-two week high of $49.88. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.27 and a current ratio of 2.12.
The business also recently announced a quarterly dividend, which was paid on Friday, June 21st. Shareholders of record on Monday, June 3rd were given a dividend of $0.04 per share. The ex-dividend date was Friday, May 31st. This represents a $0.16 annualized dividend and a dividend yield of 0.33%. Bruker’s payout ratio is currently 11.43%.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Featured Article: What is the QQQ ETF?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.